TABLE 4.
HLA A*02 modifies immune correlates of risk of HIV-1 infectiona
| Immune variable | HLA type | Est. OR | 95% CI |
P value (H0: OR = 1) | A*02+/− interaction P value | A*02+/− interaction q value | |
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| IgA C1 biotin* (positive vs negative response) | Overall | 3.15 | 1.48 | 6.71 | 0.003 | — | — |
| A*02+ | 1.26 | 0.31 | 5.15 | 0.75 | 0.13 | 0.44 | |
| A*02− | 6.01 | 2.19 | 16.5 | 0.0005 | |||
| Peptide microarray 163-TSIRDKVQKEYALFY (quantitative analysis**) | A*02+ | 0.84 | 0.42 | 1.70 | 0.63 | 0.060 | 0.41 |
| A*02− | 1.92 | 1.07 | 3.45 | 0.030 | |||
| Peptide microarray 163-TSIRDKVQKEYALFY (med vs low response***) | A*02+ | 1.71 | 0.40 | 7.37 | 0.47 | — | — |
| A*02− | 1.63 | 0.48 | 5.56 | 0.44 | — | — | |
| Peptide microarray 163-TSIRDKVQKEYALFY (high vs low response***) | A*02+ | 0.66 | 0.15 | 2.96 | 0.59 | — | — |
| A*02− | 6.04 | 1.80 | 20.3 | 0.0036 | — | — | |
a
*, OR is for vaccine recipients with a positive versus a negative response using positivity criteria determined previously (15); **, OR is per standard deviation change in the assay measurement; ***, OR is for vaccine recipients with a high (or medium) response versus a low response; —, not applicable.